ArticleIntestinal Failure (New York, N.Y.)
Healthcare cost of home parenteral nutrition and intestinal transplantation for paediatric chronic intestinal failure in Singapore.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic intestinal failure (IF) and long-term parenteral nutrition (PN) impose significant financial burden on patients and the healthcare system. This study aimed to evaluate the healthcare cost of home-PN (HPN) and intestinal transplantation (ITx) at a single-centre. Methods: This was a cost-of-illness evaluation based on retrospective analysis of billing records of patients (0-18 years) receiving HPN in 2016-2025 (excluding hospital-PN). Annual HPN cost was calculated based on average cost during the latest 3 years of HPN. Cost of ITx (since 2022) included index hospitalisation for transplant surgery and all healthcare costs in the first 3 years following ITx (ITx-Y1/Y2/Y3). Results: Out of 35 patients with chronic IF, 11 patients on HPN with dysmotility(n = 6) and short bowel syndrome(n = 5) were included (median PN-duration: 6.5 years), with 4 eventually receiving ITx. Annual cost of HPN for patients who weaned-off HPN(n = 3), versus patients who remained stable on HPN(n = 3), and patients who developed complications from irreversible IF(n = 5) was S$70,227(US$51,638)/year, S$114,359(US$84,088)/year and S$219,510(US$161,404)/year respectively. Comparatively, mean cost of index hospitalisation for ITx was S$226,316(US$166,409). Cost was highest in ITx-Y1 (S$511,905/US$376,401), followed by 66-67 % year-on-year reduction to S$172,178(US$126,601) in ITx-Y2, and S$56,152(US$41,288) in ITx-Y3. Post-transplant lymphoproliferative disorder and cytomegalovirus infection contributed to wide variation in costs in ITx-Y1. Conclusions: Cost of HPN was highest in patients with irreversible IF. While ITx incurred the highest cost in ITx-Y1, there was substantial reduction in cost in the subsequent years, which may potentially be cost-saving in the long-term, as compared to continued HPN for patients with irreversible IF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.